Antisense oligonucleotide compositions and methods for the modul

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

435 6, 435183, 435194, 435325, 435366, 435375, 536 231, 536 2431, 536 245, A01K 4800, C12N 1511, C12N 1585, C07H 2104

Patent

active

061332461

ABSTRACT:
Compositions and methods for the treatment and diagnosis of diseases or disorders amenable to treatment through modulation of expression of a gene encoding a Jun N-terminal kinase (JNK protein) are provided. Oligonucleotide are herein provided which are specifically hybridizable with nucleic acids encoding JNK1, JNK2 and JNK3, as well as other JNK proteins and specific isoforms thereof. Methods of treating animals suffering from diseases or disorders amenable to therapeutic intervention by modulating the expression of one or more JNK proteins with such oligonucleotide are also provided. Methods for the treatment and diagnosis of diseases or disorders associated with aberrant expression of one or more JNK proteins are also provided. Methods for inducing apoptosis and for treating diseases or conditions associated with a reduction in apoptosis are also provided.

REFERENCES:
patent: 4309404 (1982-01-01), Deneale et al.
patent: 4309406 (1982-01-01), Guley et al.
patent: 4556552 (1985-12-01), Porter et al.
patent: 4689320 (1987-08-01), Kaji
patent: 4704295 (1987-11-01), Porter et al.
patent: 4806463 (1989-02-01), Goodchild et al.
patent: 5004810 (1991-04-01), Draper
patent: 5034506 (1991-07-01), Summerton et al.
patent: 5087617 (1992-02-01), Smith
patent: 5098890 (1992-03-01), Gewirtz et al.
patent: 5135917 (1992-08-01), Burch
patent: 5138045 (1992-08-01), Cook et al.
patent: 5166195 (1992-11-01), Ecker
patent: 5212295 (1993-05-01), Cook
patent: 5218105 (1993-06-01), Cook et al.
patent: 5223618 (1993-06-01), Cook et al.
patent: 5242906 (1993-09-01), Pagano et al.
patent: 5264423 (1993-11-01), Cohen et al.
patent: 5276019 (1994-01-01), Cohen et al.
patent: 5286717 (1994-02-01), Cohen et al.
patent: 5378825 (1995-01-01), Cook et al.
patent: 5386023 (1995-01-01), Sanghvi et al.
patent: 5457191 (1995-10-01), Cook et al.
patent: 5459255 (1995-10-01), Cook et al.
patent: 5506351 (1996-04-01), McGee
patent: 5512438 (1996-04-01), Ecker
patent: 5521302 (1996-05-01), Cook
patent: 5539082 (1996-07-01), Nielsen et al.
patent: 5539083 (1996-07-01), Cook et al.
patent: 5541307 (1996-07-01), Cook et al.
patent: 5554746 (1996-09-01), Ravikumar et al.
patent: 5571902 (1996-11-01), Ravikumar et al.
patent: 5578718 (1996-11-01), Cook et al.
patent: 5587361 (1996-12-01), Cook et al.
patent: 5587469 (1996-12-01), Cook et al.
patent: 5587470 (1996-12-01), Cook et al.
patent: 5591720 (1997-01-01), Anderson et al.
patent: 5593974 (1997-01-01), Rosenberg et al.
patent: 5602240 (1997-02-01), De Mesmaeker et al.
patent: 5608046 (1997-03-01), Cook et al.
patent: 5610289 (1997-03-01), Cook et al.
patent: 5837244 (1998-11-01), Karin et al.
Gajate, C. et al. Molecular Pharmacology. Apr. 1998, vol. 53 (4), pp. 602-612, Apr. 1998.
Yu, W. et al. Molecular Carcinogenesis. Aug. 1998, vol. 22, vol. 22 (4), pp. 247-257, Aug. 1998.
Shiah, S.-G. Cancer Research. Jan. 1999, vol. 59 (2), pp. 391-398, Jan. 1999.
Ausubel et al., eds., "A Compendium of Methods from Current Protocols in Molecular Biology", Short Protocols in Molecular Biology, 2nd Ed., John Wiley & Sons, New York, 1992, pp. 3-11 to 3-44 and 4-17 to 4-18.
Ausubel et al., eds., "A Compendium of Methods from Current Protocols in Molecular Biology", Short Protocols in Molecular Biology, 2nd Ed., John Wiley & Sons, New York, 1992, pp. 2-24 to 2-30 and 4-14 to 4-29.
Ausubel et al., eds., "A Compendium of Methods from Current Protocols in Molecular Biology", Short Protocols in Molecular Biology, 2nd Ed., John Wiley & Sons, New York, 1992, pp. 10-33 to 10-35.
Alahari et al., "The fission yast prp4+ gene involved in pre-mRNA splicing codes for a predicted serine/threonine kinase and is essential for growth", Nucl. Acids Res., 1993, 21, 4079.
Albert et al., "Antisense knockouts: molecular scapels for the dissection of signal transduction", Trends Pharmacol. Sci., 1994, 15:250.
Alberts et al., eds., In: Molecular Biology of the Cell, Garland Publishing, Inc., New York, 1983, Chapter 16.
Alberts et al., Molecular Biology of the Cell, 1983, Garland Publishing Inc., New York, pp. 411-415.
Angel et al., "Oncogene jun encodes a sequence-specific trans-activator similar to AP-1", Nature, 1988, 332, 166.
Angel and Karin, "The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation", Biochim. Biophys. Acta, 1991, 1072, 129.
Benet et al., Chapter 1 In: Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Ed., Hardman et al., eds., McGraw-Hill, New York, NY, 1996, pp. 5-7.
Berge et al., "Pharmaceutical Salts," J. of Pharma Sci., 1977, 66:1.
Bernhard et al., "Direct evidence linking expression of matrix metalloproteinase 9 (92-kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells", Proc. Natl. Acad. Sci. U.S.A.
Birkedal-Hansen, "Proteolytic remodeling of extracellular matrix", Current Op. Biol., 1995, 7, 728.
Binetruy et al., "Ha-Ras augments c-Jun activity and stimulates phosphorylation of its activation domain", Nature, 1991, 351, 122.
Blume and Cevc, "Liposomes for the sustained drug release in vivo", Biochem. et Biophys. Acta, 1990, 1029, 91.
Bohmann et al., "Human Proto-Oncogene c-jun Encodes a DNA Binding Protein with Structural and Fuctional Properties of Transcription Factor AP-1", Science, 1987, 238, 1386.
Brigstock et al., "Species-Specific High Molecular Weight Forms of Basic Fibroblast Growth Factor", Growth Factors, 1990, 4, 45.
Brunton, "Drugs Affecting Gastrointestinal Functions", Chapter 38 In: Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Ed., Hardman et al., eds., McGraw-Hill, New York, NY, 1996, pp. 934-935.
Buur et al., "Penetration of 5-Fluorouracil And Prodrugs Across the Intestine of the Albino Rabbit:Evidence For Shift in absorption site from the upper to the lower region of the Gastrointestinal tract of products", J. Control Rel., 1990, 14:43.
Biedler et al., "Apology and Growth, Tumorigenicity, and Cytogenetics of Human Neuroblastoma Cells in Continuous Culture.sup.1 ", Cancer Res., 1973, 33, 2643.
Cano et al., "Parallel signal processing among mammalian MAPKs", Trends Biochem. Sci., 1995, 20, 117.
Cheng et al., "Bidirectional Regulation of p38 Kinase and c-Jun N-terminal Protein Kinase by Insulin-like Growth Factor-I*", J. Biol. Chem., 1998, 273, 14560.
Chonn and Cullis, "Recent advances in liposomal drug-delivery systems", Current Op. Biotech., 1995, 6, 698.
Cioffi et al., "Selective Inhibition of A-Raf and C-Raf mRNA Expression by Antisense Oligodeoxynucleotides in Rat Vascular Smooth Muscle Cells: Role of A-Raf and C-Raf in Serum-Induced Proliferation", (Mol. Pharmacol., 1997, 51, 383).
Cobb et al., "How Map Kinases Are Regulated", J. Biol. Chem., 1995, 270, 14843.
Crooke et al., "Progress in the development and patenting of antisense drug discovery technology", Exp. Opin. Ther. Patents, 1996, 6:855.
Crooke et al., "Pharmacokinetic Properties of Several Novel Oligonucleotide Analogs in mice", J. Pharmacol. Exp. Ther., 1996, 277:923.
Crooke et al., eds., Chapter 26 In: Antisense Research and Applications, CRC Press, Boca Raton, FL, 1993, pp. 461-469.
Dean et al., "Inhibition of protein kinase C-a expression in mice after systemic administration of phosphorothioate antisense Oligodeoxynucleotides", Proc. Natl. Acad. Sci. U.S.A., 1994, 91:11762-11766.
Derijard et al., "JNK1: A Protein Kinase Stimulated by UV Light and Ha-Ras That Binds and Phosphorylates the c-Jun Activation Domain", Cell, 1994, 76, 1025.
Fraley et al., Trends Biochem. Sci., 1981, 6, 77.
Ettinger et al., "Intrathecal Methotrexate Overdose Without Neurotoxicity", 1978, Cancer, 41, 1270, 1978.
Ewel et al., "Polyinosinic-Polycytidylic Acid Complexed with Poly-L-lysine and Carboxymethyl cellulose in Combination with Interleukin 2 in Patients with Cancer: Clinical and Immunological Effects.sup.1 ", Cancer Research.
El-Hariri et al., "The Mitigating Effects of Phosphatidylcholines on Bile Salt- and Lysophosphatidylcholine-induced", J. Pharm. Pharmacol., 1992, 44:651.
French et al., Expression of Two Related Nonstructural Proteins of Bluetongue Virus (BTV) Type 10 in Insect Cells by a Recombinant Baculovir

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Antisense oligonucleotide compositions and methods for the modul does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antisense oligonucleotide compositions and methods for the modul, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense oligonucleotide compositions and methods for the modul will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-468993

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.